文献速递湿疹皮炎与荨麻疹

度普利尤单抗超说明书用于儿童特应性皮炎的多中心回顾性分析

Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review.
PubMed 文献 · J Am Acad Dermatol · 2019-10-10

负荷剂量为4至15.5 mg/kg,维持剂量为每两周2.0至15.3 mg/kg,6至11岁组范围最宽,与使用成人全量或半量有关。相关合并症、治疗反应和不良事件与既往青少年及成人试验相当。

要点

  • 负荷剂量4至15.5 mg/kg、维持每两周2.0至15.3 mg/kg,6至11岁组范围最宽。
  • 疗效与安全性与既往青少年及成人试验相当,但12岁以下最佳剂量尚未确定。

核心结论

  • 本综述支持度普利尤单抗在儿童中的治疗反应与耐受性。
  • 12岁以下患者的最佳剂量尚未确定,药物有两种浓度是重要安全问题。

研究设计与样本

  • 多中心回顾性综述,评估因中重度特应性皮炎接受度普利尤单抗处方的儿童。
  • 共124例患儿纳入分析。

主要发现

  • 负荷剂量范围4至15.5 mg/kg,维持剂量每两周2.0至15.3 mg/kg。
  • 剂量范围在6至11岁组最宽,与使用成人全量或半量相关。
  • 相关合并症、治疗反应和不良事件与既往青少年及成人试验相当。

关键数值与推荐

  • 获得药物延迟的平均时间为9周,原因为保险支付被拒。
  • 负荷剂量4至15.5 mg/kg;维持剂量每两周2.0至15.3 mg/kg。

临床怎么用

  • 中重度特应性皮炎患儿可超说明书使用度普利尤单抗,但需面对平均约9周的保险审批延迟。
  • 6至11岁患儿用药需注意成人全量或半量选择带来的剂量范围差异,并关注两种浓度的安全使用。

局限性

  • 回顾性设计限制了数据的统一收集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is a common, chronic type 2 inflammatory skin disease, typically starting in infancy, with increased risk for subsequent extracutaneous atopic morbidities. Dupilumab is the first biologic agent targeting type 2 inflammation approved by the U.S. Food and Drug Administration (USFDA); it was licensed in 2017 for adults with moderate to severe AD and 2 years later for adolescents. Systemic treatment for pediatric AD remains a significant unmet medical need. OBJECTIVE: To analyze off-label use of dupilumab in children with AD. METHODS: Multicenter retrospective review that evaluated children who were prescribed dupilumab for moderate to severe AD. RESULTS: One hundred eleven of 124 patients (89.5%) gained access to dupilumab after a mean of 9 weeks. The dosing range was 4 to 15.5 mg/kg for the loading dose and 2.0 to 15.3 mg/kg every other week for maintenance. The range was widest for 6- to 11-year-olds and was related to use of either full or half of adult dosing. Associated morbidities, treatment response, and adverse events were comparable to those in previous adolescent and adult trials. LIMITATIONS: The retrospective design of the study limited uniform data collection. CONCLUSION: Access to dupilumab was achievable for the majority of children after a mean 9-week delay because of insurance payment denial. This review supports dupilumab response and tolerability in children. Optimal dosing for patients younger than 12 years has not been defined. Availability of the drug in 2 different concentrations is an important safety issue.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Igelman S, Kurta AO, Sheikh U, et al. Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review. J Am Acad Dermatol. 2019. PMID: 31606479. doi:10.1016/j.jaad.2019.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。